Skip to main content
Equibles
KRYS logo

KRYS · Krystal Biotech, Inc. · Metrics

Track KRYS — free

Use KRYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KRYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$305.23 -0.45 (-0.15%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$9.05B
Shares
29.63M
Volume · Nov 13 110.29K Avg daily vol (3M) 280.28K

KRYS metrics

86 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$305.23
Market cap
$9.05B

Price action

23 metrics
Price change (1W)
+1.4%
Price change (30D)
-7.5%
Price change (3M)
-8.1%
Price change (6M)
-0.3%
Price change (YTD)
+23.8%
Price change (1Y)
+51.7%
Trailing year
Price change (5Y)
+542.6%
52-week high
$378.15
52-week low
$201.21
Change from 52-week high
-19.3%
Change from 52-week low
+51.7%
Annualized volatility
39.4%
Annualized volatility (3M)
37.7%
Implied volatility (30D)
42.9%
IV rank (1Y)
38.7
IV percentile (1Y)
47.4
Beta
0.8
RSI (14D)
43.0
Price vs SMA 50
-6.6%
Price vs SMA 200
-1.4%
Avg volume (3M)
280,275
Relative volume
0.4
Average dollar volume
$92.39M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
29.63M

Valuation

12 metrics
P / E (TTM)
41.5
Trailing earnings · reciprocal yield 2.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
19.2×
reciprocal yield 5.2%
P / book
6.3
reciprocal yield 15.9%
FCF yield
3.4%
TTM · current market cap
Buyback yield
—
P / FCF
29.2
reciprocal yield 3.4%
P / operating cash flow
27.9
reciprocal yield 3.6%
Earnings yield
2.5%

Historical valuation

8 metrics
P / E historical average (3Y)
38.6×
reciprocal yield 2.6%
P / E historical average (5Y)
38.6×
reciprocal yield 2.6%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-02

Profitability

9 metrics
Gross margin
—
Operating margin
48.4%
Trailing 12 months
Net margin
47.9%
Gross profit (TTM)
—
Operating profit (TTM)
$227.52M
Net income (TTM)
$225.17M
Trailing 12 months
Diluted EPS (TTM)
$7.36
FCF margin
66.0%
Effective tax rate
13.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$15.36
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$7.43
EBITDA per diluted share (TTM)
$-5.44
Net income per diluted share (TTM)
$7.36
Operating cash flow per diluted share (TTM)
$10.59
Free cash flow per diluted share (TTM)
$10.13
Capital expenditures per diluted share (TTM)
$0.45
R&D per diluted share (TTM)
$1.95
Stock compensation per diluted share (TTM)
$1.81
Book value per share
$41.78

Growth

11 metrics
Revenue growth YoY
+30.2%
Year over year
Net income growth YoY
-20.5%
Revenue (TTM)
$470.02M
Trailing 12 months
EPS growth YoY
-22.9%
Shares change YoY
+3.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
15.7%
Return on assets
14.2%
Debt / equity
—
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
$310.08M
Quick ratio
7.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$462.84M
Total assets
$1.59B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$323.93M
Capital expenditures (TTM)
$13.85M
R&D (TTM)
$59.53M
SG&A (TTM)
$156.06M
Stock compensation (TTM)
$55.47M
R&D / revenue
12.7%
Stock compensation / revenue
11.8%

Ownership (13F)

9 metrics
13F filers
425
13F filer change QoQ
+54
Institutional ownership
103.7%
Conviction holders (share of 13F filers)
2.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.5%
Holder tenure
16.3
Price vs estimated holder cost
+122.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
28.3%

Short interest

3 metrics
Short interest
10.3%
Latest settlement · 12.2 days to cover
Days to cover
12.2d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$17.97M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1711279 CUSIP 501147102 13F (30d) 365 filings 333 filers Visit website Investor relations